Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01634750 |
Recruitment Status :
Completed
First Posted : July 6, 2012
Last Update Posted : October 19, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
- Hereditary inclusion body myopathy (HIBM) is a genetic disorder caused by mutations in a gene called GNE. This gene is responsible for producing a sugar called sialic acid. Low levels of sialic acid may cause muscle problems. Symptoms of HIBM include walking difficulties and muscle weakness, which usually start in a person s 20s or 30s and become worse over time.
Researchers are studying a drug called ManNAc. It may be useful for treating HIBM. However, this drug is still being tested. Researchers want to see how ManNAc is absorbed into and removed from the blood. They will not be looking specifically at whether ManNAc can stop or slow the symptoms of HIBM.
Objectives:
- <TAB>To study how MaNAc is absorbed into and removed from the blood in people with HIBM.
- <TAB>To study of safety of ManNAc in people with HIBM.
Eligibility:
- Individuals between 18 and 70 years of age who have HIBM.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
- Participants will have a 3 to 4-day inpatient stay for the main part of the study.
- Participants will be divided into groups of six. In each group, four will take ManNAc and two will take a placebo. Participants will not know which one they will receive.
- Participants will have a single dose of either ManNAc or placebo. They will be monitored for any possible side effects. Frequent blood samples will be collected during the 4-day stay.
- No treatment for HIBM will be provided as part of this study.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hereditary Inclusion Body Myopathy (HIBM) GNE Myopathy | Drug: ManNAc | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 26 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) |
Study Start Date : | September 11, 2012 |
Actual Study Completion Date : | May 29, 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: ManNac |
Drug: ManNAc
Single dose |
Placebo Comparator: Placebo |
Drug: ManNAc
Single dose |
- To evaluate the safety and tolerability of a single dose of orally administered ManNAc to HIBM subjects.
- Pharmacokinetics

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- INCLUSIONI CRITERIA:
- Subject is 18-70 years, either gender, inclusive.
- Subject has a diagnosis of HIBM (or IBM2, GNE myopathy, DMRV or Nonaka myopathy) based upon a consistent clinical course and identification of 2 GNE mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study.
- Subject must be willing to stop any treatment with ManNAc, sialic acid, IVIG, and/or other supplements containing sialic acid (eg, St John s wort, sialyllactose) 30 days prior to randomization and remain off such treatment for the duration of the trial.
- Subject has the ability to travel to the NIH Clinical Center (CC) for admissions.
- Subject (if a woman of reproductive age) must be willing to use an effective method of contraception for the duration of the trial.
- Subject provides written informed consent.
EXCLUSION CRITERIA:
- Subject has a severe disease manifestation that would interfere with the ability to comply with the requirements of this protocol.
- Subject has a psychiatric illness or neurological disease that would interfere with the ability to comply with the requirements of this protocol. This includes, but is not limited to, uncontrolled/untreated psychotic depression, bipolar disorder, schizophrenia, substance abuse or dependence, antisocial personality disorder, or panic disorder.
- Subject has hepatic laboratory parameters (AST, ALT, GGTP), or renal laboratory parameters (creatinine, BUN) greater than 3 times the upper limit of normal.
- Subject has a QTcB >450 msec (males) or QTcB >470 msec (females).
- Subject is anemic (defined as two standard deviations below normal for age and gender).
- Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires immediate surgical intervention.
- Subject is pregnant or breastfeeding at any time during the study.
- Subject has received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 4 weeks of initial screening.
- Subject has a hypersensitivity to ManNAc or in the judgment of the investigator, has a condition that places the subject at increased risk for adverse effects.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01634750
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Nuria Carrillo-Carrasco, M.D. | National Human Genome Research Institute (NHGRI) |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | National Human Genome Research Institute (NHGRI) |
ClinicalTrials.gov Identifier: | NCT01634750 |
Other Study ID Numbers: |
120207 12-HG-0207 |
First Posted: | July 6, 2012 Key Record Dates |
Last Update Posted: | October 19, 2017 |
Last Verified: | February 24, 2017 |
N-Acetyl-D-mannosamine (ManNAc) HIBM GNE Myopathy |
Muscular Diseases Distal Myopathies Musculoskeletal Diseases Neuromuscular Diseases |
Nervous System Diseases Muscular Dystrophies Muscular Disorders, Atrophic Genetic Diseases, Inborn |